Table 1 The most affected KEGG pathways after exposure to pendimethalin or its reference commercial formulation in MCF-10 A predicted from transcriptome analysis. Statistically overrepresented KEGG pathway (adjusted p-value < 0.05) are shown along their adjusted p-value (ns, non significant)
Name | Formulation | Pendimethalin |
|---|---|---|
Ubiquitin mediated proteolysis | 0.00009 | 0.0002 |
Spliceosome | 0.00009 | 0.0002 |
Metabolic pathways | 0.0001 | 0.00005 |
Nucleocytoplasmic transport | 0.0001 | 0.0003 |
Huntington disease | 0.0003 | 0.002 |
Cell cycle | 0.001 | 0.0003 |
Protein processing in endoplasmic reticulum | 0.002 | 0.0008 |
Parkinson disease | 0.005 | 0.001 |
Ribosome | 0.006 | 0.0003 |
Pyrimidine metabolism | 0.006 | 0.008 |
Endocytosis | 0.006 | 0.03 |
Lysosome | 0.006 | 0.006 |
Adherens junction | 0.01 | ns |
Oxidative phosphorylation | 0.02 | 0.006 |
Wnt signaling pathway | 0.03 | 0.008 |
mRNA surveillance pathway | 0.03 | 0.001 |
Inositol phosphate metabolism | 0.04 | ns |
Alzheimer disease | ns | 0.01 |
RNA degradation | ns | 0.02 |
Ribosome biogenesis in eukaryotes | ns | 0.02 |
Valine, leucine and isoleucine degradation | ns | 0.03 |
Renal cell carcinoma | ns | 0.04 |
Nucleotide excision repair (NER) | ns | 0.04 |
Amino sugar and nucleotide sugar metabolism | ns | 0.04 |